





Considerations on the pharma sector in Romania

Dr. Roberto Musneci



Issues

	 Innovators	 Genericists	 Distributors	 Patients
Claw-back tax				
Innovatives list				
Generics pricing				
System funding				
Availability in Romania			★	
C/V negotiations				

★ Conflicting interest with innovators

Some personal conclusions

The burden of the “new list” is a false dilemma under the current CB (for the state!).

Revision of Order 75 for GX pricing is a diversion under the current CB (for the state!).

The real (and only) debate should be on BAT.

CV is only a “Progressive CB”.

CVR are not for now!

Combination of CB+CV creates:

- *double taxation,*
- *level playing field issues,*
- *confusion.*

The “old” IMF inspired formula for CB was more equitable than the current one.

The Troika should be the first target for strategic communication to increase BAT in light of current almost zero deficit.

Only a cohesive set of measures agreed and communicated as a whole can de-tension the system

